IART Stock Recent News
IART LATEST HEADLINES
Value investing is essentially about selecting stocks that are cheap but fundamentally sound. TSN, GM, MGNI & IART boast a low P/CF ratio.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PRINCETON, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2024 financial results on Monday, November 4, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.
Integra's strong growth in the Tissue Technologies and CSS business segment bolsters investors' confidence in the stock.
The company published its third ESG report, underscoring its values and commitment to restoring lives The company published its third ESG report, underscoring its values and commitment to restoring lives
Integra's (IART) second-quarter 2024 results reflect strong demand for its diverse portfolio of leading brands and the continued successful market adoption of CereLink.
Integra LifeSciences IART reported upbeat second-quarter earnings and lowered its FY24 guidance below estimates on Monday.
Integra Lifesciences topped analysts' Q2 revenue and earnings estimates. However, the company reduced its full-year guidance.
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Integra LifeSciences (IART) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.71 per share a year ago.